LeMaitre Vascular (NASDAQ:LMAT) Receives New Coverage from Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report report published on Tuesday, Marketbeat Ratings reports. The brokerage issued a neutral rating and a $96.00 price target on the medical instruments supplier’s stock.

A number of other analysts also recently issued reports on LMAT. StockNews.com downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a report on Tuesday, August 27th. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They set a buy rating and a $105.00 target price for the company. JMP Securities upped their target price on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a market outperform rating in a research report on Tuesday, August 20th. Finally, Barrington Research reiterated an outperform rating and issued a $92.00 price target on shares of LeMaitre Vascular in a research report on Friday, September 20th. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $94.67.

LeMaitre Vascular Stock Down 1.0 %

Shares of LMAT opened at $91.24 on Tuesday. The business has a 50-day simple moving average of $88.42 and a two-hundred day simple moving average of $81.05. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $93.32. The stock has a market cap of $2.05 billion, a price-to-earnings ratio of 60.42, a PEG ratio of 2.45 and a beta of 0.88.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. The company had revenue of $55.85 million during the quarter, compared to analyst estimates of $54.98 million. During the same period in the prior year, the firm posted $0.37 EPS. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. On average, equities analysts anticipate that LeMaitre Vascular will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the transaction, the director now owns 14,114 shares of the company’s stock, valued at $1,158,335.98. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.79% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in LeMaitre Vascular by 2.5% in the 4th quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares during the period. PNC Financial Services Group Inc. grew its stake in LeMaitre Vascular by 4.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,858 shares of the medical instruments supplier’s stock worth $673,000 after purchasing an additional 555 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in LeMaitre Vascular by 28.3% in the first quarter. Los Angeles Capital Management LLC now owns 22,505 shares of the medical instruments supplier’s stock worth $1,493,000 after purchasing an additional 4,960 shares in the last quarter. Congress Asset Management Co. MA raised its position in LeMaitre Vascular by 12.0% during the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after purchasing an additional 71,411 shares in the last quarter. Finally, Bridge City Capital LLC raised its position in LeMaitre Vascular by 2.7% during the 1st quarter. Bridge City Capital LLC now owns 73,204 shares of the medical instruments supplier’s stock valued at $4,858,000 after purchasing an additional 1,890 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.